MX2021011084A - Metodos de terapia antitumoral. - Google Patents
Metodos de terapia antitumoral.Info
- Publication number
- MX2021011084A MX2021011084A MX2021011084A MX2021011084A MX2021011084A MX 2021011084 A MX2021011084 A MX 2021011084A MX 2021011084 A MX2021011084 A MX 2021011084A MX 2021011084 A MX2021011084 A MX 2021011084A MX 2021011084 A MX2021011084 A MX 2021011084A
- Authority
- MX
- Mexico
- Prior art keywords
- tumor
- methods
- tumor therapy
- vector
- subject
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Abstract
La invención proporciona métodos para inducir o mejorar una respuesta antitumoral en un sujeto que tiene un tumor, que comprenden administrar al sujeto una dosis de preparación de un vector que comprende un gen quimera Fas enlazado operativamente a un promotor específico de células endoteliales, en donde la dosis de preparación del vector se administra antes de la extirpación quirúrgica del tumor o una porción del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962817735P | 2019-03-13 | 2019-03-13 | |
PCT/IB2020/052260 WO2020183424A1 (en) | 2019-03-13 | 2020-03-12 | Methods of anti-tumor therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021011084A true MX2021011084A (es) | 2021-10-22 |
Family
ID=70058427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021011084A MX2021011084A (es) | 2019-03-13 | 2020-03-12 | Metodos de terapia antitumoral. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220154212A1 (es) |
EP (1) | EP3937959A1 (es) |
JP (1) | JP2022524321A (es) |
KR (1) | KR20210139329A (es) |
CN (1) | CN113784730A (es) |
AU (1) | AU2020234098A1 (es) |
BR (1) | BR112021017780A2 (es) |
CA (1) | CA3131936A1 (es) |
IL (1) | IL286198A (es) |
MX (1) | MX2021011084A (es) |
SG (1) | SG11202109173UA (es) |
WO (1) | WO2020183424A1 (es) |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7727761B2 (en) | 1995-08-01 | 2010-06-01 | Vegenics Limited | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
CA2286330C (en) | 1997-04-07 | 2008-06-10 | Genentech, Inc. | Anti-vegf antibodies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US8039261B2 (en) | 2000-11-17 | 2011-10-18 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
US20100282634A1 (en) | 2000-11-17 | 2010-11-11 | Dror Harats | Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis |
US20070286845A1 (en) | 2000-11-17 | 2007-12-13 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
DK1487856T3 (da) | 2002-03-04 | 2010-10-18 | Imclone Llc | KDR-specifikke humane antistoffer og deres anvendelse |
ES2523457T3 (es) | 2004-11-18 | 2014-11-26 | Imclone Llc | Anticuerpos contra el receptor 1 del factor de crecimiento endotelial vascular |
ES2572356T3 (es) | 2007-11-09 | 2016-05-31 | Peregrine Pharmaceuticals Inc | Composiciones de anticuerpos dirigidos contra VEGF y procedimientos |
SG10201500048SA (en) | 2010-01-05 | 2015-03-30 | Vascular Biogenics Ltd | Compositions and methods for treating glioblastoma gbm |
SG10201500013SA (en) | 2010-01-05 | 2015-03-30 | Vascular Biogenics Ltd | Methods for use of a specific anti-angiogenic adenoviral agent |
US20130320253A1 (en) | 2010-10-18 | 2013-12-05 | Total Research & Trchnogy Feluy | Expandable vinyl aromatic polymers |
PT2908865T (pt) * | 2012-10-17 | 2019-01-11 | Vascular Biogenics Ltd | Adenovírus que expressa uma quimera de fas e sua utilização em métodos de tratamento de cancro |
WO2014118643A2 (en) * | 2013-02-04 | 2014-08-07 | Vascular Biogenics Ltd. | Methods of inducing responsiveness to anti-angiogenic agent |
-
2020
- 2020-03-12 EP EP20715962.5A patent/EP3937959A1/en not_active Withdrawn
- 2020-03-12 CN CN202080031953.8A patent/CN113784730A/zh active Pending
- 2020-03-12 CA CA3131936A patent/CA3131936A1/en active Pending
- 2020-03-12 JP JP2021551894A patent/JP2022524321A/ja active Pending
- 2020-03-12 WO PCT/IB2020/052260 patent/WO2020183424A1/en unknown
- 2020-03-12 SG SG11202109173UA patent/SG11202109173UA/en unknown
- 2020-03-12 AU AU2020234098A patent/AU2020234098A1/en not_active Abandoned
- 2020-03-12 US US17/438,840 patent/US20220154212A1/en active Pending
- 2020-03-12 MX MX2021011084A patent/MX2021011084A/es unknown
- 2020-03-12 BR BR112021017780A patent/BR112021017780A2/pt not_active Application Discontinuation
- 2020-03-12 KR KR1020217032557A patent/KR20210139329A/ko unknown
-
2021
- 2021-09-06 IL IL286198A patent/IL286198A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021017780A2 (pt) | 2022-02-01 |
EP3937959A1 (en) | 2022-01-19 |
US20220154212A1 (en) | 2022-05-19 |
KR20210139329A (ko) | 2021-11-22 |
WO2020183424A1 (en) | 2020-09-17 |
AU2020234098A1 (en) | 2021-09-16 |
SG11202109173UA (en) | 2021-09-29 |
JP2022524321A (ja) | 2022-05-02 |
CN113784730A (zh) | 2021-12-10 |
CA3131936A1 (en) | 2020-09-17 |
IL286198A (en) | 2021-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20220037A1 (ar) | جسيمات نانوية دهنية محسنة لتوصيل الأحماض النووية | |
MX2021003554A (es) | Proteinas de union a dll3 y metodos de uso. | |
MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
MX2022010270A (es) | Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion. | |
AU2017234929B2 (en) | Therapeutic for treatment of diseases including the central nervous system | |
WO2019226514A3 (en) | Molecular gene signatures and methods of using same | |
NZ728265A (en) | Methods to enhance organ transplant and antibody therapies | |
MX2020010694A (es) | Particulas de raav que codifican mir-708 y usos del mismo. | |
MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
MX2017011633A (es) | Uso de composiciones que contienen peptido inhibidor de mk2 para tratar cancer de pulmon de celulas no pequeñas con las mismas. | |
MX2016013025A (es) | Focalizacion de cancer de mama her2+ resistente a trastuzumab con una nanoparticula dirigida de her3. | |
EA202090700A1 (ru) | Компетентные по репликации аденовирусные векторы | |
MX2020013313A (es) | Terapia genica cardiaca con aav para cardiomiopatia. | |
PH12020500570A1 (en) | Alpha-synuclein antisense oligonucleotides and uses thereof | |
CY1124812T1 (el) | Μεθοδος ανοσοενισχυτικης θεραπευτικης αντιμετωπισης του καρκινου | |
ES2897599T3 (es) | Mejora de la administración de genes a células asesinas naturales, células madre hematopoyéticas y macrófagos | |
MX2018015172A (es) | Metodos para tratar cancer pancreatico. | |
SG10201907746TA (en) | Methods of treating cancer harboring hemizygous loss of tp53 | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
MX2021011084A (es) | Metodos de terapia antitumoral. | |
EA202192757A1 (ru) | Способ лечения опухолей | |
AU2018251949A1 (en) | Compounds, composition and uses thereof for treating cancer | |
MX2022004836A (es) | Vacunas mejoradas para la papilomatosis respiratoria recurrente y métodos para su uso. | |
MX2021012398A (es) | Metodos de terapia antitumoral. | |
GB2502017A (en) | Molecular targets for healing or treating wounds |